Advanced Flower Capital Inc.
AFCG Nasdaq Financials FY2021βFY2025
What Advanced Flower Capital Inc. does
No business description yet.
- Legal name
- Advanced Flower Capital Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 4, 2026
- Accession Β· CIK
- 0001628280-26-014392
0001822523
Revenue and margins
Advanced Flower Capital Inc. had $24.6M of revenue in fiscal 2025, down 46.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Advanced Flower Capital Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 6.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Advanced Flower Capital Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $109M | $140M | $90.4M | $104M | $38.6M |
| Total assets | $465M | $519M | $467M | $402M | $276M |
| Total liabilities | $192M | $180M | $147M | $201M | $100M |
| Shareholders' equity | $273M | $339M | $320M | $201M | $176M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 |
| Accruals ratio | 2.5% | 0.9% | β0.1% | β1.1% | β9.4% |
| Altman Z'' | β | β | β | β | β |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $37.0M | $74.7M | $63.9M | $45.7M | $24.6M |
| Net interest income | $37.0M | $74.7M | β | β | β |
| Provision for credit losses | $2.6M | β | β | β | β |
| Interest expense | $1.1M | $6.8M | $6.4M | $6.3M | $6.8M |
| Pretax income | $21.0M | $37.0M | $22.4M | $14.3M | β$21.3M |
| Income tax | $0.0M | $1.0M | $1.7M | $0.4M | β$0.6M |
| Net income | $21.0M | $35.9M | $21.0M | $16.8M | β$20.7M |
| Net income to common | β | $35.8M | $20.7M | $16.3M | β$21.0M |
| Diluted EPS | $1.52 | $1.79 | $1.02 | $0.78 | β$0.95 |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | |||||
| Cash from operations | $9.5M | $31.3M | $21.2M | $21.6M | $11.2M |
| Stock-based compensation | $1.7M | $1.3M | $1.0M | $1.4M | $6.8M |
| Dividends paid | $14.4M | $41.6M | β | β | β |
| Dividends and buybacks | $14.4M | $41.6M | β | β | β |
| Balance sheet | |||||
| Cash and short-term investments | $109M | $140M | $90.4M | $104M | $38.6M |
| Loans, net | $257M | β | β | β | β |
| Total assets | $465M | $519M | $467M | $402M | $276M |
| Total liabilities | $192M | $180M | $147M | $201M | $100M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $273M | $339M | $320M | $201M | $176M |
| Margins | |||||
| Net margin | 56.7% | 48.1% | 32.8% | 36.8% | β84.2% |
| Net interest share of revenue | 100.0% | 100.0% | β | β | β |
| Returns | |||||
| Return on equity | 7.7% | 11.7% | 6.4% | 6.4% | β11.0% |
| Return on assets | 4.5% | 7.3% | 4.3% | 3.9% | β6.1% |
| Return on tangible equity | 7.7% | 10.6% | 6.5% | 8.1% | β12.0% |
| Growth | |||||
| Revenue growth | β | 101.8% | β14.4% | β28.6% | β46.2% |
| Net income growth | β | 71.1% | β41.7% | β19.9% | β223.2% |
| EPS growth | β | 17.8% | β43.0% | β23.5% | β221.8% |
| Share count change | β | 44.5% | 1.9% | 2.7% | 6.7% |
| Financial health | |||||
| Provision / loans | 1.0% | β | β | β | β |
| Capital allocation | |||||
| Stock comp / revenue | 4.7% | 1.8% | 1.5% | 3.0% | 27.8% |
| Quality scores | |||||
| Accruals ratio | 2.5% | 0.9% | β0.1% | β1.1% | β9.4% |
Source: SEC EDGAR XBRL filings (CIK 0001822523). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.